p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1369-1380

  Shao, Changxia ^a   Lu, Chuanwen ^a   Chen, Lixia ^a   Koty, Patrick P ^b   Cobos, Everardo ^c   Gao, Weimin ^a,c  

^a TEXAS TECH UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Cytotoxicity; Gene array; Leptomycin B; Lung adenocarcinoma; p53

Indexed keywords

LEPTOMYCIN B; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; P21 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVIN GENE; WILD TYPE;

ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, UNSATURATED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MUTATION; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959619518     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1434-6     Document Type: Article

References (66)

1. Garcia M, Jemal A, Ward EM et al (2007) Global Cancer Facts & Figures 2007. American Cancer Society, Atlanta
2. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
3. Hecht SS (2005) Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new. Carcinogenesis 26:1488-1492
4. Devesa SS, Bray F, Vizcaino AP et al (2005) International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117:294-299 (Pubitemid 41379403)
5. American Cancer Society (2009) Cancer Facts & Figures 2009. American Cancer Society, Atlanta
6. Bunn PA Jr, Thatcher N (2008) Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist 13 Suppl 1:37-46
7. Ramalingam S, Belani C (2008) Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13 Suppl 1:5-13
8. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
9. Greenblatt MS, Bennett WP, Hollstein M et al (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878 (Pubitemid 24289415)
10. Gao WM, Mady HH, Yu GY et al (2003) Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types. Lung Cancer 40:141-150 (Pubitemid 36438714)
11. Bennett WP, Hussain SP, Vahakangas KH et al (1999) Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 187:8-18 (Pubitemid 29009831)
12. Foo RS, Nam YJ, Ostreicher MJ et al (2007) Regulation of p53 tetramerization and nuclear export by ARC. Proc Natl Acad Sci USA 104:20826-20831
13. Fried H, Kutay U (2003) Nucleocytoplasmic transport: taking an inventory. Cell Mol Life Sci 60:1659-1688 (Pubitemid 37041364)
14. Mutka SC, Yang WQ, Dong SD et al (2009) Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 69:510-517
15. Kau TR, Way JC, Silver PA (2004) Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 4:106-117 (Pubitemid 38198739)
16. van der Watt PJ, Maske CP, Hendricks DT et al (2008) The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 124:1829-1840
17. Shen A, Wang Y, Zhao Y et al (2009) Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 65:153-159 discussion 159-160
18. Huang WY, Yue L, Qiu WS et al (2009) Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 32:E315
19. Komiyama K, Okada K, Tomisaka S et al (1985) Antitumor activity of leptomycin B. J Antibiot (Tokyo) 38:427-429 (Pubitemid 15102209)
20. Yoshida M, Nishikawa M, Nishi K et al (1990) Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cells. Exp Cell Res 187:150-156
21. Roberts BJ, Hamelehle KL, Sebolt JS et al (1986) In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114, 721). Cancer Chemother Pharmacol 16:95-101
22. Macara IG (2001) Transport into and out of the nucleus. Microbiol Mol Biol Rev 65:570-594
23. Cook A, Bono F, Jinek M et al (2007) Structural biology of nucleocytoplasmic transport. Annu Rev Biochem 76:647-671
24. Hoshino I, Matsubara H, Komatsu A et al (2008) Combined effects of p53 gene therapy and leptomycin B in human esophageal squamous cell carcinoma. Oncology 75:113-119
25. Freedman DA, Levine AJ (1998) Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18:7288-7293 (Pubitemid 28533048)
26. Lecane PS, Kiviharju TM, Sellers RG et al (2003) Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate 54:258-267 (Pubitemid 36228162)
27. Caglieri A, Goldoni M, De Palma G et al (2008) Exposure to low levels of hexavalent chromium: target doses and comparative effects on two human pulmonary cell lines. Acta Biomed 79 Suppl 1:104-115
28. Smart P, Lane EB, Lane DP et al (1999) Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 18:7378-7386 (Pubitemid 30032119)
29. Yang B, Eshleman JR, Berger NA et al (1996) Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 2:1649-1657 (Pubitemid 26356347)
30. Giannakakou P, Poy G, Zhan Z et al (2000) Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 19:3078-3085 (Pubitemid 30438464)
31. Lowe SW, Schmitt EM, Smith SW et al (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849 (Pubitemid 23132161)
32. Clarke AR, Purdie CA, Harrison DJ et al (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852 (Pubitemid 23132162)
33. Lowe SW, Ruley HE, Jacks T et al (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967 (Pubitemid 23289454)
34. Shaw P, Bovey R, Tardy S et al (1992) Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89:4495-4499
35. Kuerbitz SJ, Plunkett BS, Walsh WV et al (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495
36. Fan S, el-Deiry WS, Bae I et al (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54:5824-5830
37. Wahl AF, Donaldson KL, Fairchild C et al (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72-79 (Pubitemid 26029571)
38. Zhang CC, Yang JM, White E et al (1998) The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 16:1617-1624 (Pubitemid 28159910)
39. Yu X, Robinson JF, Gribble E et al (2008) Gene expression profiling analysis reveals arsenic-induced cell cycle arrest and apoptosis in p53-proficient and p53-deficient cells through differential gene pathways. Toxicol Appl Pharmacol 233:389-403
40. Wang XW (1999) Role of p53 and apoptosis in carcinogenesis. Anticancer Res 19:4759-4771
41. Fischer M, Skowron M, Berthold F (2005) Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J Mol Diagn 7:89-96
42. Gaj S, Eijssen L, Mensink RP et al (2008) Validating nutrient-related gene expression changes from microarrays using RT(2) PCR-arrays. Genes Nutr 3:153-157
43. Shimo A, Nishidate T, Ohta T et al (2007) Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci 98:174-181 (Pubitemid 44941869)
44. Le Gac G, Esteve PO, Ferec C et al (2006) DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1. J Biol Chem 281:24161-24170 (Pubitemid 44274190)
45. Mirza A, McGuirk M, Hockenberry TN et al (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613-2622 (Pubitemid 34478319)
46. Tu SP, Jiang XH, Lin MC et al (2003) Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63:7724-7732 (Pubitemid 37466703)
47. Knauer SK, Kramer OH, Knosel T et al (2007) Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 21:207-216 (Pubitemid 46052558)
48. Saxena A, Rorie CJ, Dimitrova D et al (2006) Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. Oncogene 25:7274-7288 (Pubitemid 44809093)
49. Wawrzynow B, Zylicz A, Wallace M et al (2007) MDM2 chaperones the p53 tumor suppressor. J Biol Chem 282:32603-32612 (Pubitemid 350159272)
50. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10:1054-1072 (Pubitemid 26152848)
51. Lee YS, Wan J, Kim BJ et al (2006) Ubiquitin-dependent degradation of p53 protein despite phosphorylation at its N terminus by acetaminophen. J Pharmacol Exp Ther 317:202-208
52. Menendez S, Higgins M, Berkson RG et al (2003) Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein. Br J Cancer 88:636-643 (Pubitemid 36363376)
53. Milutinovic S, Knox JD, Szyf M (2000) DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21 (WAF1/CIP1/sdi1). J Biol Chem 275:6353-6359 (Pubitemid 30129929)
54. Tan HH, Porter AG (2009) p21(WAF1) negatively regulates DNMT1 expression in mammalian cells. Biochem Biophys Res Commun 382:171-176
55. Duriez C, Moyret-Lalle C, Falette N et al (2004) BTG2, its family and its tutor. Bull Cancer 91:E242-E253
56. Hay N (2008) p53 strikes mTORC1 by employing sestrins. Cell Metab 8:184-185
57. Cooper WA, Kohonen-Corish MR, Zhuang L et al (2008) Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions. Cancer 113:135-142 (Pubitemid 351976394)
58. Jang BC, Paik JH, Jeong HY et al (2004) Leptomycin B-induced apoptosis is mediated through caspase activation and down-regulation of Mcl-1 and XIAP expression, but not through the generation of ROS in U937 leukemia cells. Biochem Pharmacol 68:263-274
59. Vigneri P, Wang JY (2001) Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 7:228-234 (Pubitemid 32148491)
60. Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 19:17-24
61. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer's double-edged sword acting as both facilitator and gate-keeper of malignancy when bound to mitochondria. Oncogene 25:4777-4786 (Pubitemid 44187625)
62. Pelaez R, Herrero P, Moreno F (2009) Nuclear export of the yeast hexokinase 2 protein requires the Xpo1 (Crm1)-dependent pathway. J Biol Chem 284:20548-20555
63. Kim W, Yoon JH, Jeong JM et al (2007) Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther 6:2554-2562 (Pubitemid 47480421)
64. Bihl M, Tamm M, Nauck M et al (1998) Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. Am J Respir Cell Mol Biol 19:606-612 (Pubitemid 128354242)
65. Regis G, Icardi L, Conti L et al (2009) IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. Leukemia 23:2102-2108
66. Moodley YP, Misso NL, Scaffidi AK et al (2003) Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol 29:490-498 (Pubitemid 37222687)